Amid swirling speculation, Bausch + Lomb ($BLCO), a global leader in the contact lens supply industry, is reportedly ...

Roula Khalaf, Editor of the FT, selects her favourite stories in this weekly newsletter. Private equity groups TPG and Blackstone have teamed up to work on a joint bid for eyecare company Bausch ...

including Biotrue and SofLens. We are still impressed at the overall performance and believe the firm's share in the contact lens market slightly increased. Miebo and Xiidra, Bausch & Lomb's dry ...

Wells Fargo analyst Larry Biegelsen maintained a Buy rating on Bausch + Lomb Corporation (BLCO – Research Report) yesterday and set a ...

Monday was an eventful day for Bausch + Lomb (NYSE: BLCO). The eye care specialist's major piece of internal news was that it earned its latest Food and Drug Administration (FDA) approval.

Bausch + Lomb shares surged Monday following reports Blackstone and TPG are considering teaming up to buy the eyecare company. A bid from Blackstone and TPG could reportedly value the company ...

H.C. Wainwright analyst Yi Chen reiterated a Buy rating on Bausch + Lomb Corporation (BLCO – Research Report) today and set a price ...

Bausch + Lomb scaled up its revenue guidance for the year after swinging to a profit in the latest quarter on the back of sales growth in each of its business segments.

VAUGHAN, Ontario (AP) — VAUGHAN, Ontario (AP) — Bausch + Lomb Corporation (BLCO) on Wednesday reported third-quarter net income of $4 million, after reporting a loss in the same period a year earlier.

Continued progress on the buyout of Bausch & Lomb is lifting shares, with the stock up over 6% at the time of writing. Financial Times reported on Oct. 14 that two prominent figures involved in ...